Age is an independent prognostic factor, and young women are more likely to be diagnosed with more aggressive biological subtypes: triple-negative (lacking estrogen and progesterone receptor expression in tumor cell nuclei and without HER2 gene amplification) and HER-2 positive [2]. Here, ERBB2 is linked to neoplasm.